NCT02839720View on ClinicalTrials.gov

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 26, 2017

Primary Completion Date

November 5, 2022

Study Completion Date

August 31, 2023

Conditions
Cutaneous NeurofibromaNeurofibromatosis Type 1Optic Nerve Glioma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Selumetinib Sulfate

Given PO

Trial Locations (2)

20892

National Institutes of Health Clinical Center, Bethesda

35233

University of Alabama at Birmingham Cancer Center, Birmingham

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02839720 - Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | Biotech Hunter | Biotech Hunter